Antiastenic effect of sequential levocarnitine and acetylcarnitine therapy in patients with cardiovascular diseases

Close metadata

OBJECTIVE

Evaluation of the antiasthenic effect of sequential therapy with levocarnitine (LC) and acetylcarnitine (ALC) in patients with arterial hypertension and/or ischemic heart disease (CHD) with asthenic syndrome (AS).

MATERIAL AND METHODS

An open comparative study included 120 patients aged 54—67 years in patients with arterial hypertension and/or coronary artery disease with AS. Patients of group1 (n=60), in addition to basic therapy for the underlying disease, received LC (Elcar solution for intravenous and intramuscular injection of 100 mg/ml, the company PIQ-PHARMA) intravenously for 10 days at a dose of 1000 mg/day, followed by a transition to oral administration of ALC (Carnicetine, the company PIQ-PHARMA) 500 mg (2 capsules) 2 times a day for 2 months. Group2 patients (n=60) received only basic therapy for major diseases. The duration of observation was 70 days. The severity of AS was assessed using the MFI-20 questionnaire (MultidiMensional Fatigue Inventory) and the visual analog scale VAS-A (Visual Analog Scale Measuring fatigue).

RESULTS

In patients of group1, a statistically significant decrease in various manifestations of AS was noted. The differences were significant both in comparison with the baseline level and in comparison with the 2nd group. The endothelium-protective effect of LC and ALC has been established.

CONCLUSION

The results obtained indicate that in such comorbid patients, the use of LC and ALC reduces the severity of AS manifestations, and the established endotheliotropic properties of the drugs allow them to be recommended as part of the complex personalized therapy of patients with cardiovascular diseases.

Keywords:

cardiovascular diseases

moderate cognitive deficit

levocarnitine

acetylcarnitine

Elcar

Carnicetine

endothelial dysfunction

Authors:

Statsenko M.E.

Volgograd State Medical University

ORCID: 0000-0002-3306-0312

Turkina S.V.

Volgograd State Medical University

Received:

27.10.2022

Accepted:

21.11.2022

List of references:

ICD-10/ICD-10. International Classification of Diseases (10th revision). Classification of Mental and behavioral disorders. Clinical descriptions and guidelines for diagnosis. World Health Organization. SPb. 1994. (In Russ).
Williams JE, Mosley TH Jr, KopWJ, et al. Vital exhaustion as a risk factor for adverse cardiac events (from the Atherosclerosis Risk In Communities [ARIC] study). Am J Cardiol. 2010;105(12):1661-1665. https://doi.org/10.1016/j.amjcard.2010.01.340
Eckhardt AL, Devon HA, Piano MR, et al. Fatigue in the presence of coronary heart disease. Nurs Res. 2014;63(2):83-93. https://doi.org/10.1097/NNR.0000000000000019
Voznesenskaia TG, Fokina NM, Iakhno NN. TreatMent of asthenic disorders in patients with psychoautonomic syndroMe: results of a multicenter study on efficacy and safety of ladasten. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2010;5:17-25. (In Russ.).
Guthrie E. Medically unexplained symptoms in primary care. Advances In Psychiatric TreatMent. 2008;14(7):432-440. https://doi.org/10.1192/apt.bp.106.003335
Nelesen R, Dar Y, Thomas K, Dimsdale JE. The relationshipbetween fatigue and cardiac functioning. Arch Intern Med. 2008;168(9):943-949. https://doi.org/10.1001/archinte.168.9.943
Mangold SA, M Das J. Neuroanatomy, Reticular Formation. [Updated 2020 Aug 15]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. https://www.ncbi.nlm.nih.gov/books/NBK556102
Sokolova LP, Starykh EV. Asthenic syndroMe in general therapeutic practice. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2022;122(4):44-51. (In Russ.). https://doi.org/10.17116/jnevro202212204144
Kuratsune H, Yamaguti K, Takahashi M, et al. Acylcarnitine deficiency in chronic fatigue syndroMe. Clin Infect Dis. 1994;18(1):62-67. https://doi.org/10.1093/clinids/18.suppleMent_1.s62
Reuter SE, Evans AM. Long-chain acylcarnitine deficiency in CFS. Potential involveMent of altered carnitin. J Int Med. 2011;270(1):76-84. https://doi.org/10.1111/j.1365-2796.2010.02341.x
Statsenko ME, Turkina SV. Possibilities of sequential levocarnitin and acetylcarnitin treatMent in correcting cognitive deficiency in patients with cardiovascular diseases. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(5):45-51. (In Russ.). https://doi.org/10.17116/jnevro202112105145
Smets EM, Garssen B, Bonke B, De Haes JC. The Multidi Mensional Fatigue Inventory (MFI): psychoMetric qualities of instruMent to assess fatigue. J Pshychosom Res. 1995;39(3):315-325. https://doi.org/10.1016/0022-3999(94)00125-O
Alves E, Binienda Z, Carvalho F, et al. Acetyl-L-carnitine provides effective in vivo neuroprotection over 3,4-MethylenedioxiMethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brain. Neuroscience. 2009;158:514-523. https://doi.org/10.1016/j.neuroscience.2008.10.041
Jones LL, McDonald DA, Borum PR. Acylcarnitines: role in brain. Prog Lipid Res. 2010;49(7):61-75. https://doi.org/10.1016/j.plipres.2009.08.004
Zanelli SA, Solenski NJ, Rosenthal RE, Fiskum G. Mechanisms of ischemic neuroprotection by acetyl-L-carnitine. Ann NY Acad Sci. 2005;1053:153-161.
Patel SP, Sullivan PG, Lyttle TS, et al. Acetyl-L-carnitine treatMent following spinal cord injury improves mitochondrial function correlated with remarkable tissue sparing and functional recovery. Neuroscience. 2012;210(7):296-307. https://doi.org/10.1016/j.neuroscience.2012.03.006
Zhang R, Zhang H, Zhang Z, et al. Neuroprotective effects of pre-treatMent with l-carnitine and acetyl-L-carnitine on ischemic injury in vivo and in vitro. Int J Mol Sci. 2012;13:2078-2090. https://doi.org/10.3390/ijms13022078
Xu Y, Jiang W, Chen G, et al. L-carnitine treat- Ment of insulin resistance: A systematic review and Meta-analysis. Adv Clin ExpMed. 2017;26(2):333-338. https://doi.org/10.17219/acem/61609
Zhao M, Jiang Q, Wang W, et al. The Roles of Reactive Oxygen Species and Nitric Oxide in Perfluorooctanoic Acid-Induced DevelopMental Cardiotoxicity and l-Carnitine Mediated Protection. Int J Mol Sci. 2017;18(6):1229. https://doi.org/10.3390/ijms18061229
Mohammadi M, Hajhossein TA, Alidoosti M. Preventive effect of l-carnitine and its deriva- tives on endothelial dysfunction and platelet aggregation. Clin Nutr ESPEN. 2016;15(5):1-10. https://doi.org/10.1016/j.clnesp.2016.06.009
Fan Z, Han Y, Ye Y, et al. L-Carnitine preserves cardiac function by activating p38 MAPK/Nrf2 signalling in hearts exposed to irradiation. Eur J Pharmacol. 2017;804(6):7-12. https://doi.org/10.1016/j.ejphar.2017.04.003
Wang S, Xu J, Zheng J, et al. Anti-Inflammatory and Antioxidant Effects of Acetyl-L-Carnitine on Atherosclerotic Rats. Med Sci Monit. 2020;26:e920250. https://doi.org/10.12659/MSM.920250
da Silva Guimarães S, de Souza Cruz W, da Silva L, et al. Effect of L-Carnitine SuppleMentation on Reverse Remodeling in Patients with Ischemic Heart Disease Undergoing Coronary Artery Bypass Grafting: A Randomized, Placebo-Controlled Trial. Ann Nutr Metab. 2017;70(2):106-110. https://doi.org/10.1159/000465531
Li M, Xue L, Sun H, Xu S. Myocardial Protective Effects of L-Carnitine on Ischemia-Reperfusion Injury in Patients With Rheumatic Valvular Heart Disease Undergoing Cardiac Surgery. J Cardiothorac Vasc Anesth. 2016;30(6):1485-1493. https://doi.org/10.1053/j.jvca.2016.06.006
Graziano F, Bisonni R, Catalano V, et al. Potential role of levocarnitine suppleMentation for the treatMent of chemotherapy-induced fatigue in non-anaemic cancer patients. Br J Cancer. 2002;86(5):1854-1857. https://doi.org/10.1038/sj.bjc.6600413
Tomassini V, Pozzilli C, Onesti E, et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatMent of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci. 2004;218(1-2):103-108. https://doi.org/10.1016/j.jns.2003.11.005
Traina G, Federighi G, Macchi M, et al. Modulation of myelin basic protein gene expression by acetyl-L-carnitine. Mol Neurobiol. 2011;44(3):1-6. https://doi.org/10.1007/s12035-011-8189-x
Kuratsune H, Watanabe Y, Yamaguti K, et al. High uptake of [2-11C]acetyl-L-carnitine into the brain: a PET study. Biochem Biophys Res Commun. 1997;231(7):488-493. https://doi.org/10.1006/bbrc.1996.5919
Baloni P, Nho K, Arnold M, et al. Investigating the importance of acylcarnitines in AlzheiMer’s disease. AlzheiMer’s DeMent. 2021;17(7):e056647.
Scafidi S, Fiskum G, Lindauer SL, et al. Metabolism of acetyl-L-carnitine for energy and neurotransmitter synthesis in the immature rat brain. J Neurochem. 2010;114:820-831. https://doi.org/10.1111/j.1471-4159.2010.06807.x
Aureli T, Puccetti C, Di Cocco ME, et al. Entry of [(1,2-13C2)acetyl]-L-carnitine in liver tricarboxylic acid cycle and lipogenesis: a study by 13C NMR spectroscopy in conscious, freely moving rats. Eur J Biochem. 1999;263:287-293. https://doi.org/10.1046/j.1432-1327.1999.00524.x
Januszewicz E, Pajak B, Gajkowska B, et al. Organic cation/carnitine transporter OCTN3 is present in astrocytes and is upregulated by peroxisoMe proliferators-activator receptor agonist. Int J Biochem Cell Biol. 2009;41:2599-2609. https://doi.org/10.1016/j.biocel.2009.08.020
Ferreira GC, McKenna MC. L-Carnitine and Acetyl-L-carnitine Roles and Neuroprotection in Developing Brain. Neurochem Res. 2017;42(6):1661-1675. https://doi.org/10.1007/s11064-017-2288-7
Chiechio S, Canonico PL, Grilli M. L-Acetylcarnitine: A Mechanistically Distinctive and Potentially Rapid-Acting Antidepressant Drug. International Journal of Molecular Sciences. 2018;19(1):11. https://doi.org/10.3390/ijms19010011
Malaguarnera M, Bella R, Vacante M, Iordano M, et al. Acetyl-L-carnitine re- duces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scand J Gastroenterol. 2011;46:750-759. https://doi.org/10.1007/s10620-008-0238-6
Astashkin EI, Glezer MG. Effect of L-carnitine on oxidative stress at cardiovascular diseases. Meditsinskiy sovet = Medical Council. 2016;4(10):104-110. (In Russ.). https://doi.org/10.21518/2079-701X-2016-10-104-110
Astashkin EI, Glezer MG. The role of L-carnitine in the energetic Metabolism of cardiomyocytes and treatment of cardio-vascular diseases. Kardiologiya i Serdechno-Sosudistaya Khirurgiya. 2012;5(6):58-65. (In Russ.).

Close metadata